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Abstract 25 
Background: Despite numerous studies and meta-analyses the prognostic effect of cardiac rehabilitation (CR) is still 26 
under debate. This update of the Cardiac Rehabilitation Outcome Study (CROS II) provides a contemporary and 27 
practice focused approach including only CR interventions based on published standards and core components to 28 
evaluate CR delivery and effectiveness in improving patient`s prognosis. 29 
Design: Systematic review and meta-analysis  30 
Methods: Randomized controlled trials (RCT) and retrospective and prospective controlled cohort studies (rCCS, pCCS) 31 
evaluating patients after acute coronary syndrome (ACS), coronary bypass grafting (CABG) or mixed populations with 32 
coronary artery disease (CAD) published until Sep 2018 were included. 33 
Results: Based on CROS inclusion criteria out of 7,096 abstracts 6 additional studies including 8,671 patients were 34 
identified (2 RCT, 2 rCCS; 2 pCCS). In total, 31 studies including n=228,337 patients were available for this meta-analysis 35 
(3 RCT, 9 pCCS, 19 rCCS; patients after ACS: n=50,653, after CABG: n=14,583, mixed CAD populations: n=163,101; 36 
follow-up periods ranging from 9 months up to 14 years).  37 
Heterogeneity in design, CR delivery, biometrical assessment and potential confounders was considerable. CCS 38 
showed a significantly reduced total mortality (primary endpoint) after CR participation in patients after ACS [pCCS: 39 
hazard ratio (HR) 0.37, 95% confidence interval (CI): 0.20-0.69; rCCS: HR 0.64, 95% CI 0.53-0.76; pCCS: odds ratio (OR) 40 
0.20, 95% CI 0.08-0.48], but the single RCT fulfilling the CROS inclusion criteria showed neutral results. CR participation 41 
also was associated with reduced total mortality in patients after CABG (rCCS: HR 0.62, 95% CI 0.54-0.70, one single 42 
RCT without fatal events), and in mixed CAD populations (rCCS: HR 0.52, 95% CI 0.36-0.77; 2 out of 10 CCS with neutral 43 
results). 44 
Conclusion: CROS II confirms the effectiveness of CR participation after ACS and after CABG in actual clinical practice 45 
by reducing total mortality under the conditions of current evidence-based CAD treatment. The data of CROS II, 46 
however, underscore the urgent need to define internationally accepted minimal standards for CR delivery as well as 47 
for scientific evaluation. 48 
Word count: 325 49 
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 52 
Introduction 53 
Within the past 25 years, cardiovascular morbidity and mortality after acute coronary syndromes (ACS) showed 54 
remarkable decrease which is associated with the implementation of acute coronary revascularizations as well as the 55 
application of effective acute and long-term pharmacotherapy.1 Supporting these results from the United States1 the 56 
French FAST-MI registry revealed a mortality reduction six months after ST-elevation myocardial infarction (STEMI) 57 
and Non-ST-elevation myocardial infarction (NSTEMI) from 17.2% to 5.3% and 6.3% respectively.2 Moreover, on the 58 
basis of the SWEDEHEART registry a marked improvement of 2-years survival was found, but strictly associated with 59 
the use of acute coronary interventions and evidence-based long-term secondary prevention.3 Accordingly, current 60 
evidence-based treatment modalities of ACS and CAD do have a large impact on acute and long-term success of care 61 
delivered to these patients. Against this background the effects of special treatment modalities like cardiac 62 
rehabilitation (CR) need to be re-evaluated in light of their added short and long-term clinical and prognostic benefit. 63 
The Cardiac Rehabilitation Outcome Study (CROS) aimed to evaluate the prognostic effect of CR after ACS and coronary 64 
artery bypass grafting (CABG) in the modern era of cardiovascular treatment modalities. On the basis of predominantly 65 
controlled observational studies including a large amount of patients, CROS confirmed a beneficial effect of CR (i.e. 66 
reduced all cause mortality after ACS and after CABG).4 However, with CROS  it became apparent that minimal 67 
requirements for CR delivery (based on published standards and core components)5 ?8 had to be fulfilled to reach 68 
effectiveness. These minimal requirements have been addressed  by other recent meta-analyses9 ?13 with a focus on 69 
volume and intensity of exercise sessions and treatment of CV risk factors during CR. Not meeting these minimal 70 
requirements may explain in part the negative results of some recent studies and meta-analyses.14 ?16 71 
Against this background, the aim of this CROS-update was to critically re-evaluate the results of CROS I in the light of 72 
newly published CR studies meeting the strict CROS inclusion criteria. Moreover, the aim of this update was to 73 
further elucidate the CR-effect on secondary and non-fatal clinical endpoints representing a heterogeneous field in 74 
clinical CR research. By evaluating controlled observational studies the CROS data finally reflect everyday clinical care 75 
thereby allowing an estimation of how guideline standards are actually translated into clinical practice. 76 
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 77 
Methods 78 
This review was conducted and reported according to the PRISMA statement (Preferred Reporting Items for 79 
Systematic Reviews and Meta-Analyses), and the MOOSE statement (Meta-analysis Of Observational Studies 80 
in Epidemiology).17,18 The core methods used were essentially unchanged compared to the 2016 81 
publication. The study protocol was prospectively published in PROSPERO (CRD42014007084).19 82 
Study eligibility criteria  83 
Randomized controlled trials (RCT) as well as prospective and retrospective controlled cohort studies (pCCS, 84 
rCCS) of multi-component CR versus usual care, with a follow-up period of at least six months, were 85 
investigated. We included men and women of all ages after hospitalization for ACS or CABG, respectively. In 86 
addition, we included studies enrolling mixed populations of patients after ACS and/or after CABG as basic 87 
requirement, as well as patients with chronic stable coronary artery disease (CAD) with or without elective 88 
percutaneous coronary intervention (PCI). Patient enrolment had to be carried out by 1995 or later. The 89 
primary endpoint was total mortality. Secondary endpoints mainly included non-fatal cardiovascular events, 90 
hospital readmissions and mixed endpoints. The detailed study selection criteria were previously presented 91 
(see LINK TO SUPPLEMENTAL MATERIAL, Table SM 1).4 92 
Search methods and identification of studies  93 
For the previous review4 highly sensitive search strategies were developed to identify two types of studies: 94 
RCT and CCS regardless of the studies´ current status (published, unpublished, finished or ongoing). A 95 
detailed description of the elaboration of the search strategy is available in the previous review.4 96 
For this update, we restricted our search to the following four databases: PubMed, Embase, Cochrane 97 
Central Register of Controlled Trials and the World Health Organization´s International Clinical Trials Registry 98 
Platform (ICTRP). Databases, which did not contribute studies for inclusion in the previous review, were no 99 
longer deployed. The search informing this update comprised the period 23 December 2015  ? 4 September 100 
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2018. No language restrictions were applied. Details of all search strategies are documented in supplemental 101 
material (LINK TO SUPPLEMENTAL MATERIAL, Table SM 2). In addition to searching electronic databases, the 102 
references of recent systematic reviews were screened. 103 
Study selection  104 
The titles and abstracts of all references were independently evaluated by at least two members of the 105 
reference selection board (AS, CHD, BR). Abstracts of potential interest were re-evaluated and selected for 106 
full text evaluation (FTE) and structured study evaluation (SSE), respectively, consented within the whole 107 
board. FTE for assessing main inclusion criteria and SSE with quality assessment was performed and 108 
consented within an extended reference selection board (AS, CHD, BR, PD) including a biometrician (KJ). The 109 
primary reasons for study exclusion are given in Table SM 4 (online version, supplemental material). 110 
For the meta-analysis, the studies resulting from the SSE process of the current update were merged with 111 
the selected studies from the 2016 publication. The study selection process is outlined in Figure 1. 112 
Study evaluation process 113 
The study evaluation included design, data sources, information on population, interventions, controls, 114 
calculation and presentation of outcomes and handling of bias. For RCT the Cochrane risk of bias table 115 
(http://tech.cochrane.org/revman/download), and for the CCS the checklists of methodological issues on 116 
non-randomized studies,20,21 and the Newcastle Ottawa Scale (NOS) were used.22 To facilitate the study 117 
evaluation with respect to management of confounding, age, gender, smoking, diabetes, history of stroke, 118 
history of acute myocardial infarction (AMI), reduced left ventricular ejection fraction and acute or early PCI 119 
during AMI have been pre-specified as potential confounders. 120 
Data extraction 121 
Data extraction was performed by two biometricians independently (KJ, MH), using a standardized 122 
extraction form. Disagreements were solved by consensus. We extracted the following information from 123 
each eligible article: name of first author, year of publication, study location (country), study design, data 124 
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source, number of participants, population (ACS, CABG or mixed), inclusion period, inclusion criteria, follow-125 
up time, mean age of participants, proportion of men, intervention characteristics, control characteristics, 126 
reported outcomes, information on outcomes, data on outcomes, covariates included in the adjusted 127 
models. 128 
Statistical analysis 129 
The analyses were separated with regard to population (AMI, CABG or mixed) and study design (RCT, 130 
pCCSand rCCS). For time-to-event outcomes, the hazard ratio (HR) with its 95% confidence interval was 131 
chosen as effect measure per study. If possible, log HRs and their standard errors were extracted directly, 132 
preferably from an adjusted model and matched-group analysis. If they were not reported but adequate 133 
univariate analyses were available, an indirect estimation method was used.23,24 In some study 134 
publications, instead of HR adjusted odds ratios (OR) at the end of follow-up or only absolute numbers of 135 
events to calculate ORs were reported. HRs and ORs were reported and pooled separately in the present 136 
review.25 For dichotomous outcomes, the OR with its 95% confidence interval was used as the effect 137 
measure per study. If no event occured in one or in both arms, a continuity correction of 0.5 per cell was 138 
applied. For consistency, we re-calculated the treatment effect to be in the same direction, as necessary, 139 
with an HR or OR above 1 indicating a higher risk for CR with respect to each outcome. HRs were combined 140 
using the generic inverse-variance method. ORs were pooled using the Mantel-Haenszel method or the 141 
generic inverse-variance method. The latter one was used when at least one study reported an adjusted OR. 142 
Random-effects models were used to calculate overall effect estimates and confidence intervals because we 143 
ĂƐƐƵŵĞĚ ŚĞƚĞƌŽŐĞŶĞŝƚǇ ďĞƚǁĞĞŶ ƚŚĞ  ‘ƚƌƵĞ ? ĞĨĨĞĐƚƐ ŽĨƚŚĞ ĚŝĨĨĞƌĞŶƚ CR programs used in the studies. All 144 
results were investigated for statistical heterogeneity by I2 statistics with 0-30% representing no or only 145 
small, 30-60% moderate, 50-90% substantial and 75-100% considerable heterogeneity.26 A statistical 146 
investigation of potential publication bias based on a test of funnel plot asymmetry could not be done 147 
because of too few studies per single meta-analysis.26 Nevertheless, sensitivity analyses for the outcome 148 
total mortality have been performed with respect to extracted results of alternative analysis techniques (e.g. 149 
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independent groups instead of matched groups). There are some deviations from the review protocol 150 
published in PROSPERO.19 ORs instead of  RRs were used as effect measure for dichotomous outcomes 151 
because in some studies adjusted ORs and no absolute numbers are reported. Furthermore, it was not 152 
possible to undertake the planned subgroup analyses due to the small number of studies in each subgroup. 153 
R version 3.5.1 (R Foundation for Statistical Computing, 2015) and the R  “meta ? package version 4.9-2 154 
(developed by Guido Schwarzer) was used for all statistical analyses. 155 
Results 156 
Study characteristics  157 
Study characteristics (design, population, interventions, controls and primary results) of the newly identified 158 
studies are presented in Table 1. With respect to the design, only 2 RCT (n=240 patients) fulfilled the CROS 159 
criteria increasing the total number of RCT to 3 (n=2,053 patients). In addition, 2 rCCS (n=5,238 patients) and 160 
2 pCCS (n=3,193 patients) were newly identified. Thus, a total of 18 rCCS (n=211,334 patients) and 9 pCCS 161 
(n=15,386 patients) were considered for final analysis.  162 
Three new studies enrolled 4,315 patients after ACS (total of 15 studies; n=50,653 patients), one additional 163 
study included 36 patients after CABG (total of 10 studies; n=14,583 patients), while 2 newly identified 164 
studies recruited 4,320 patients in  “mixed populations ? (total of 11 studies; n=163,101 patients).  165 
ZƐĞƚƚŝŶŐǁĂƐ “ŽƵƚ-ƉĂƚŝĞŶƚ ?ŝŶĂůůŶĞǁƐƚƵĚŝĞƐ ?ƚŽƚĂůŽĨ ? ? ? and CR duration varied from 12 weeks to 12 166 
months, thereby not changing the range of 3-4 weeks up to 12 months identified in the previous CROS study. 167 
Moreover, the previously reported  “CR intensity ?ranging from 2 up to more than 5 exercise sessions per 168 
week plus motivation, information, education, and psychosocial interventions with variable intensities and 169 
combinations remained unchanged. 170 
Notably, the included studies reveal a considerable heterogeneity not only with respect to the predefined 171 
study designs (RCT, pCCS, rCCS), and populations (after ACS, after CABG, mixed CAD populations), but also 172 
with respect to study endpoints and biometrical evaluation (Tables 2, 3a/b and Fig. 2). For this reason, the 173 
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majority of the secondary endpoints predefined by CROS could not be integrated into a meta-analysis (Table 174 
2, Figure 2). 175 
Primary endpoint  “ƚŽƚĂůŵŽƌƚĂůŝƚǇ ? 176 
A summary of the clinical outcomes is shown in Table 2 ? dŚĞ ƉƌŝŵĂƌǇ ĞŶĚƉŽŝŶƚ  “ƚŽƚĂů ŵŽƌƚĂůŝƚǇ ? ǁĂƐ177 
evaluated in 27 studies, one of them evaluating both, mortality after ACS and after CABG (Figure 2).27 178 
Participation in CR was associated with a significant reduction of total mortality in all but 6 studies.14,28 ?32  179 
After ACS a significant reduction of total mortality was confirmed by the newly added pCCS (4 studies, HR 180 
0.37, 95% CI 0.20-0.69; I²=28%) and even strengthened by the newly added rCCS (4 studies; HR 0.64, 95% CI 181 
0.53-0.76; I2=33%).  182 
After CABG, the newly identified single RCT was small, only enrolling n=36 low risk patients. During a follow-183 
up period of one year, no deaths occurred, and the risk of  “underpowering ? has to be regarded as high in 184 
this study (see Table 3b, Figure 2).. No additional rCCS or pCCS were identified; consequently, the previous 185 
positive results on mortality reduction remained unchanged in this population.  186 
/Ŷ “ŵŝǆĞĚƉŽƉƵůĂƚŝŽŶƐ ?ƚŚĞĂĚĚŝƚŝŽŶŽĨŽŶĞŵŽƌĞƉ^ĐŽŶĨŝƌŵĞĚƚŚĞƐŝŐŶŝĨŝĐĂŶƚŵŽƌƚĂůŝƚǇƌĞĚƵĐƚŝŽŶŝŶ CR 187 
participants (2 studies; HR 0.66, 95% CI 0.55-0.79) with zero heterogeneity. No additional rCCS calculating 188 
HR within the mixed populations could be included by the current search (HR 0.52, 95% CI 0.36-0.77, I²=84%). 189 
The single rCCS newly added within the group calculating OR did not change the neutral result reported 190 
before in this group (3 studies, OR 0.68, 95% CI 0.34-1.37) but heterogeneity was high (I2=94%). Sensitivity 191 
analyses did not change the overall results. 192 
Secondary endpoints 193 
The results of CROS II with respect to the secondary endpoints are listed in Table 2, differentiating between 194 
the various study designs, populations and biometrical approaches. These results are summarized as follows: 195 
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Regarding the secondary ĞŶĚƉŽŝŶƚƐ “sŵŽƌƚĂůŝƚǇ ? ?3 additional studies, 7 studies in total ?ĂŶĚ “D ? ? ?196 
studies, unchanged) all selected studies considerably differed with respect to populations and designs, and 197 
Ă “ŵĂƚĐŚŝŶŐ ?of these studies for meta-analysis was not possible (Table 2). Focusing on ƚŚĞĞŶĚƉŽŝŶƚ “CV 198 
ŵŽƌƚĂůŝƚǇ ?and based on the two large controlled observational studies (pCCS, rCCS) there might be a trend 199 
in favor of CR participation after ACS and after CABG. With regard to the endpoint MACCE, however, the 200 
selected studies do not allow a final conclusion on the effect of CR-participation (Table 2).  201 
dŚĞŽƵƚĐŽŵĞƐ “ŶŽŶ-ĨĂƚĂůD/ ? ?ƚŽƚĂů ?ƐƚƵĚŝĞƐ ?ĂŶĚ “ŶŽŶ-ĨĂƚĂůƐƚƌŽŬĞ ? ?ƚŽƚĂů ?ƐƚƵĚŝĞƐ ?also did not show a 202 
clear trend, but all studies varied in design and population thus hindering a further evaluation by meta-203 
analysis. 204 
The same is true for studies investigating the variably predefined endpoints for  “ŚŽƐƉŝƚĂů ƌĞĂĚŵŝƐƐŝŽŶ ? 205 
(endpoints 6-9, see Methods). Most of these studies had heterogeneous designs, and  matching of the 206 
studies for meta-analysis was not possible (Table 2).  207 
In a ĚĞƐĐƌŝƉƚŝǀĞǁĂǇƚŚĞƌĞƐƵůƚƐŽŶ “ŚŽƐƉŝƚĂůƌĞĂĚŵŝƐƐŝŽŶ ?may be summarized as follows: all studies included 208 
in CROS either showed a reduction of hospital readmissions in favor of CR-participation, or there was a 209 
neutral result. In 12 studies, combined endpoints with various components were evaluated. One more RCT 210 
has been identified showing a statistically reduced combined end-point (death, recurrent acute coronary 211 
events, or hospitalization for HF) after CR participation compared to usual care (HR=0.26, 95% CI 0.09 ?212 
0.73).33  213 
Quality evaluation of the studies:  214 
The sum of positive adjudications estimated by NOS is presented in Table 3a (for details see online version, 215 
supplemental material: Table SM 5). Four additional studies were graded within a range of 5-7. In total, 5 216 
out of 28 studies (18%) were graded with 5 points or less. Limitations were found with respect to 217 
representativeness (6 studies), comparability of the cohorts (3 studies), adequacy of follow-up (5 studies), 218 
and the assessment of outcomes (2 studies). 219 
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On the basis of the checklist of methodological issues on non-randomized studies the following limitations 220 
were identified (Tables 3a/b): 221 
Three studies were based on a secondary analysis of original studies with different original objectives  222 
In 3 studies, either time or location differences between the study groups were apparent.  223 
In most studies, the group ĨŽƌŵĂƚŝŽŶǁĂƐƉŽƚĞŶƚŝĂůůǇŝŶĨůƵĞŶĐĞĚďǇŚĞĂůƚŚĐĂƌĞĚĞĐŝƐŝŽŶŵĂŬĞƌƐĂŶĚƉĂƚŝĞŶƚ ?Ɛ224 
preferences.  225 
The majority of the studies had unclear study protocols and a consort flow diagram was presented only in 226 
seven out of 28 studies  227 
Management of confounding was not reported in 3 studies, whereas the description of potential 228 
confounding domains remained unclear or has not been reported in 16 studies.  229 
Predefinition and calculation of all confounding domains as pre-specified by CROS (see Materials and 230 
Methods) were performed to various degrees. In only 4 studies all 8 predefined confounders were 231 
considered for adjustment. Moreover, 6 studies only considered 3 or even less confounders as predefined 232 
by CROS. In general, adjustment for confounding was performed in 24 CCS with 4 studies not applying 233 
adequate biometrical methods.  234 
ŽƚŚZd ĞǀĂůƵĂƚŝŶŐ ƚŚĞ ƉƌŝŵĂƌǇ ĞŶĚƉŽŝŶƚ  “ƚŽƚĂů ŵŽƌƚĂůŝƚǇ ? ĚŽ ŚĂǀĞ Ă ĐŽŶƐŝĚĞƌĂďůĞ ƌŝƐŬ ŽĨ ďĞŝŶŐ235 
underpowered (Table 3b).14,30,33 236 
 237 
Discussion 238 
This update of the Cardiac Rehabilitation Outcome Study (CROS II) confirms the beneficial prognostic effect 239 
of CR in CAD patients by significantly reducing ƚŚĞƉƌŝŵĂƌǇĞŶĚƉŽŝŶƚ “ƚŽƚĂůŵŽƌƚĂůŝƚǇ ?especially after ACS or 240 
CABG. However, the effects of CR-participation on ƐĞĐŽŶĚĂƌǇ ĞŶĚƉŽŝŶƚƐ ůŝŬĞ  “s-ŵŽƌƚĂůŝƚǇ ? ?  “ŶŽŶ ĨĂƚĂů241 
ŵǇŽĐĂƌĚŝĂů ŝŶĨĂƌĐƚŝŽŶ ? ?  “ŶŽŶ ĨĂƚĂů ƐƚƌŽŬĞ ? ?  “ĐŽŵďŝŶĞĚ ĞŶ ƉŽŝŶƚƐ ? ĂŶĚ ǀĂƌŝŽƵƐ ĨŽƌŵƐ ŽĨ  “ŚŽƐƉŝƚĂů242 
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ƌĞĂĚŵŝƐƐŝŽŶ ?ƌĞŵĂŝŶůĞƐƐĐůĞĂƌ ?dŚŝƐ at least in part - is due to a considerable heterogeneity of the selected 243 
studies with respect to design, populations, predefined endpoints and biometry. Inconsistent results may be 244 
due to the kind of selected endpoints ŝŶĐůƵĚŝŶŐ “ǁĞĂŬ ?ĞŶĚƉŽŝŶƚƐǁŝƚŚŝŶĐƌĞĂƐĞĚƌŝƐŬƐŽĨĐŽŶĨŽƵŶĚŝŶŐ ?This 245 
is particularly true for the variable forms of  “ŚŽƐƉŝƚĂů ƌĞ-ĂĚŵŝƐƐŝŽŶ ? ? ǁŚŝĐŚ ŵĂǇ ďĞ ŝŶĨůƵĞŶĐĞĚby local 246 
routines in medical services, individual comorbidities not necessarily associated with CV diseases, and the 247 
individual`s disease perception. Moreover, a longer survival of patients after AMI/CABG may reveal other 248 
diseases that primarily determine the number of hospital admissions during prolonged follow-up.   249 
With regard to the secondary ĞŶĚƉŽŝŶƚ “ŶŽŶ-fatal AMI ?ĂŶŽǀĞƌĂůů “ŶĞƵƚƌĂů ?ĞĨĨĞĐƚĂůƐŽŚĂƐďĞen reported 250 
by Cochrane (Anderson et al. 2016). As AMI and death are closely interrelated clinical events one might 251 
speculate that CR-participation effectively prevents death initiated by AMI, but also reduces the incidence 252 
of AMI (fatal + non-fatal) per se, resulting in an apparent  “ŶĞƵƚƌĂůĞĨĨĞĐƚ ? with respect to non-fatal AMI 253 
occurrence. Unfortunately, the data sources presently available for CROS do not allow to further evaluate 254 
this hypothesis.   255 
One of the major strengths of this study is its robust approach to CR intervention aligned with published 256 
national CR standards and core components.5 ?7 Our strict definition of a comprehensive multi-component 257 
CR underscores the importance of the amount of physical exercise provided, the adherence to exercise 258 
intervention and the adherence to non-exercise components on the patientƐ ? ƉƌŽŐŶŽƐŝƐ ? dŚĞ ƌĞƐƵůƚƐ ŽĨ259 
recently published meta-analyses (some of them including studies of the modern era of novel medication 260 
and interventions) seem to support this approach and somehow elucidate our results. Thus, van Halewijn et 261 
al. have shown that a significant reduction in all-cause mortality was feasible in CAD patients only under the 262 
condition of a comprehensive CR program managing six or more CV risk factors,10 while the recently 263 
published EU-CaRE study showed positive effects of comprehensive CR in 58% of older patients with three 264 
or more uncontrolled risk factors before CR.34 These findings, coupled with CROS II results, strengthen 265 
clinical recommendations that comprehensive CR is preferable to standalone exercise based CR in reducing 266 
total and cardiac mortality, in post-MI patients.13 The effectiveness of a comprehensive CR program is 267 
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increased by the pĂƚŝĞŶƚ ?ƐĂĚŚĞƌĞŶĐĞĂŶĚďǇƚŚĞshared effort to consequently assess and treat the majority 268 
of all individual CV risk factors.  269 
With regards to the importance of the CR dose, Santiago de Araujo Pio et al. established that total mortality 270 
reduction was only possible in cardiovascular disease patients experiencing medium and high doses of CR.12 271 
Similar CR dose and volume related effects on mortality have been published.9,35 Finally, in a systematic 272 
review of multi-component CR, applying almost all CROS inclusion criteria, the study by Sumner et al. carried 273 
out a meta-analysis of observational studies published after the year 2000, concluding that all-cause and 274 
cardiac mortality were reduced in AMI patients following a CR program.36 275 
Still, one has to keep in mind that this beneficial effect of CR-participation as shown in CROS may not apply 276 
to special subgroups like elderly and frail patients who need a particularly personalized approach.37 277 
According to Deaton C et al.38 however, the average age of the CROS study population reflects actual clinical 278 
reality. Likewise, CR participation of patients with severe systolic heart failure may not result in mortality 279 
reduction as shown in previous meta-analyses.39 ?41 280 
Apart from these limitations, CROS II presents a timely account of the effectiveness of CR when delivered to 281 
agreed published standards including scientifically proven CR core components.5 ?7 Utilizing a strict 282 
approach to CR intervention study inclusion we can report a significant benefit (Table 2 and figure 2) in favor 283 
of CR with respect to all-cause mortality. However, at the same time this approach might be viewed as a 284 
significant weakness as it makes our findings almost incompatible with previous reviews which have been 285 
much more inclusive of CR interventions often defined by innovations in CR being evaluated as part of clinical 286 
trials rather than informed by interventions based on published CR program standards and core 287 
components. Only three RCT were selected for CROS II compared to 63 in the most recent Cochrane review 288 
which reported a significant reduction in cardiovascular mortality but not in all-cause mortality.9 We are not 289 
suggesting that previous trial based reviews are erroneous. On the contrary, we agree that robust trials-290 
based reviews remain top of the evidence base hierarchy. What we are prosing is that, the CROS II approach 291 
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differs to the extent that it should be viewed as an additional form of evidence that utilizes registry-based 292 
research reflecting a broader population in the modern cardiology era from 1995 onwards.  293 
For a critical estimation of the CROS II results, the following aspects have to be emphasized: 294 
Cardiac rehabilitation participation after ACS or CABG is associated with reduced total mortality if delivered 295 
on top of the current evidence-based treatment modalities (medication and acute coronary interventions). 296 
Cardiac rehabilitation participation therefore may contribute to treatment adherence and further add 297 
effective individual life style changes necessary to significantly reduce patient`s cardiovascular risk.42 ?46 298 
This positive effect of CR participation obviously works in current clinical practice of different countries 299 
provided a minimum of CR volume and intensity is delivered. This especially refers to the individually adapted 300 
and supervised exercise training and a rigorous treatment of all individual cardiovascular risk factors. 301 
9,12,13,47 302 
Unfortunately, these prerequisites of successfully delivered CR - although outlined in detail in many position 303 
papers - are not necessarily followed in clinical practice. As noted in CROS II, these prerequisites are not 304 
sufficiently described in many clinical studies evaluating CR effectiveness. Therefore, there is an urgent need 305 
to effectively translate these well-known and evidence-based minimal standards into all day clinical practice 306 
wherever CR is offered. Moreover, these clinical standards need to be the adamant basis of future CR 307 
outcome studies. To this end, minimal standards for CR interventions in clinical practice and clinical trials 308 
should be based on robust published guidelines and research. We offer the CROS II definition and criteria as 309 
a useful guide for optimal CR intervention content and delivery; including multi-disciplinary and multi-310 
component programs with structured, supervised exercise training delivered at least twice per week in 311 
combination with motivational techniques, risk factor modification education, dietary advices, psychosocial 312 
and vocational support delivered at least once per week. The CR setting could be in-, out-patient or mixed 313 
but the time between hospital discharge and CR initiation should be as low as possible, preferably within 314 
three months.  315 
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From this background it is one of the CROS study ?Ɛ aim not only to evaluate the results and clinical outcomes 316 
of the studies included, but also to critically evaluate strengths and deficiencies in detail of each single study 317 
included into the meta-analysis (see Table 3). As in the first evaluation in CROS, this update uncovers 318 
considerable deficits in current CR studies that need to be addressed and prevented in future. These deficits 319 
include predominantly insufficient description of CR content (e.g. applied components), frequency and 320 
volume of exercise sessions, CR initiation (i.e. after hospital stay for an acute cardiac event) and duration, 321 
absence of CR adherence at follow up as well as methodological issues such as the inadequate consideration 322 
of confounding parameters at the stage of study and statistical analysis design.  323 
Clinical implications 324 
Together with the results of other recent reviews, minimal requirements for a successful CR after ACS or 325 
CABG are apparent and need to be ensured in clinical practice:4,9,10,12,13,45  326 
- Cardiac rehabilitation is multi-component including consequent treatment of the individual`s 327 
cardiovascular risk factors, individually adapted physical exercise, information, motivation as well as 328 
individualized psychosocial support.4 329 
- The individualized approach also reflects gender, age, frailty, heart failure, concomitant diseases, 330 
psychosocial background and effectors of the individual`s health and capabilities. 331 
- Cardiac rehabilitation is supervised and carried out by adequately trained health professionals 332 
including cardiologists.4 333 
- During CR the  “dose ? of exercise training (number of weeks of exercise training × average number of 334 
sessions/week × average duration of session in minutes) exceeds 1.000.9 335 
- The number of CR sessions (including physical exercise, information, education and psychosocial 336 
support) needs to exceed 36.12 337 
- During CR all individually recognized cardiovascular risk factors need to be addressed and treated.10 338 
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Consequently, future studies on the effect of CR need to report in detail whether these minimal 339 
requirements were rigorously followed by the participating CR centres. 340 
Conclusions 341 
CROS II confirms the effectiveness of CR participation after ACS and after CABG in actual clinical practice by reducing 342 
total mortality under the conditions of current evidence-based CAD treatment. The CROS approach to more strictly 343 
predefined CR intervention and to include controlled registry based studies represents a valid hybrid approach that 344 
has clear utility in clinical decision-making. 345 
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Tables 601 
Table 1. Newly identified studies selected for quantitative analysis; baseline study characteristics and overall results 602 
Study 
Publication 
year 
Country  
Study 
design 
Population (P): 
a. Data sources 
b. Number of included 
participants (N) 
c. Index events 
d. Inclusion period 
e. Other inclusion criteria 
and characteristics 
f. Age (y, mean±SD or as 
stated) 
g. Gender (male, %) 
Intervention (I): 
a. Number (n) 
b. Structured and multi-
component CR (SMC-
CR)? 
c. Start after index event 
d. Duration (time period 
and/or total number 
of CR sessions) 
e. Frequency (CR exercise 
sessions per wk) 
f. CR-setting 
Control (C): 
a. Number (n) 
b. Treatment, 
characteristics 
Outcome (O): 
a. Follow-up period 
b. Outcomes 
according to the 
CROS criteria 
(numbers 
according to 
table 1) 
c. Other outcomes 
not predefined 
by CROS II 
Overall results, with 
respect to endpoints 1 ?
10 as defined by CROS.  
Definitions are given at 
the end of the table* 
 
Remarks 
Espinosa 
Caliani S et al. 
200448 
Spain 
pCCS a. Institutional, Hospital 
Clínico Universitario 
Virgen de la Victoria, 
Málaga, Spain. 
b. N=153 
c. AMI 
d. not stated; after 1995 
e. control group did not 
accept CR program 
f. 49.9±8.4 (CR+) 
53.5±9.5 (no CR) 
g. 93.5 
a. n=113 
b. SMC-CR 
c. Immediately after 
discharge 
(phase I) 
d. 12 wk (phase II) 
at least 9 mo (phase III) 
e. n=3 (24 sessions) + 
educational talks, 
dietary and nutritional 
advice, psychological 
support (3mo, phase 
II). Maintenance phase 
III until 12 mo 
f. primary care centre 
(phase II, III) 
a. n=40 
b. CR non-attenders 
a. 1 y1 y post AMI 
b. (10) 
c. Quality of life, 
exercise 
capacity, body 
mass index 
Event rate 
(%CR+/noCR)) 
Endpoint 10 (angina, 
hospitalization, re-
infarction, cardiac 
insufficiency and/or 
death): 6.7/ 6.7 (p=NS) 
 
- Only patients with 
low-risk MI 
- CR by patients' 
decision 
- CR supervised by 
"family doctor" not 
by cardiologist 
- CR program 
accredited by 
Cardiology Spanish 
Society 
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Lee JY et al. 
201649 
Canada 
pCCS a. Data linkage: 
ASAN Medical 
Center-Left MAIN 
Revascularization 
registry (single-
center retrospective 
database) 
b. N=3,040 
c. mixed population: 
patients with 
unprotected LMCA 
stenosis >50% with 
subjective or 
objective ischemia; 
ACS (64.2%), silent 
ischemia (8%), stable 
AP (27.8%) 
d. 01/01/1995 ?
31/12/2010 
e. Patients treated with 
PCI (37.7%), CABG 
(49.1%) or medically 
(13.2%); end of follow-
up 31/08/2014 
f. 60.8±10.3 (CR+) 
62.4±10.5 (no CR) 
g. 76.2 (CR+) 
72.9 (no CR) 
a. n=596 
n=507 (matched 
pairs) 
b. SMC-CR 
c. Within 3 mo after 
index hospitalization 
(phase II) 
d. 3 mo (36 sessions) 
e. n=3  
f. outpatient 
a. n=2,444 
n=507 (matched 
pairs) 
b. CR non-
attenders 
a. Mdn 7.3y  
(IQR, 4.4- 10.2y) 
b. (1),(2),(4),(5),(8) 
c. ZŝƐŬĨĂĐƚŽƌƐ ?
modification, 
exercise capacity, 
QoL, return to 
work, 
psychological 
results 
Event rate 
(%CR+/noCR))  
Endpoint 1: 13.3/ 18.5 
Endpoint 2: 10.4/ 15.5 
Endpoint 4: 3.0/ 6.7 
p<0.001 for all 
Endpoint 5: 2.0/ 3.4 
p=0.07 
Endpoint 8: 7.3/ 10.9 
p=0.006 
HR (95% CI) after 
multivariate analysis 
Endpoint 1:  
0.70 (0.49 ?1.00); 
p=0.05 
Endpoint 2: 0.69 (0.48 ?
0.97); p=0.03 
Endpoints 4, 5, 8: p=NS 
HR (95% CI) propensity-
matched pairs 
Endpoint 1: 0.62 (0.43 ?
0.89); p=0.009 
Endpoint 2: 0.54 (0.36 ?
0.80); p=0.002 
Endpoints 4, 5, 8: p=NS 
- participation in CR 
was defined as 
attending at least 
one outpatient CR 
session (phase II) 
within 3 mo after 
index 
hospitalization 
Aronov DM et 
al. 201730 
Russia 
RCT a. Institutional 
Moscow Centre of 
Interventional 
Cardioangiology. 
b. N=36 
a. n=18  
b. SMC-CR (educational 
program + physical 
training) 
c. 2 ?8 wk after CABG 
(mean 7.8±1.6 wk) 
a. n=18 
b. CR non-
attenders; only 
educational 
a. 1 y 
b. (1), (6), (8), (10) 
c. Exercise and 
echocardiograph
y parameters, 
lipd levels, QoL, 
Event (nr CR+/nr no CR) 
Endpoint 1: 0/0 
Endpoint 6: 1/3 
Endpoint 8: 1/1 
Endpoint 10 (AP, MI, re-
vascularization, 
- publication in 
Russian language 
(translations 
received from 
Cochrane Russia 
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c. patients with IHD 
who had undergone 
CABG 
d. not stated; after 
1995 
e. -- 
f. 58.6±7.0 (CR+) 
55.9±7.0 (no CR) 
g. 100 
d. 4 mo 
e. n=3 
f. monitored (medical 
supervision) or not-
monitored (home 
based) 
program 
available 
AP attacks, return 
to work 
hospitalization for IHD 
exacerbation): 2/7 
and a private 
agency) 
- no statistical 
analyses of the 
results 
- CR had educational 
component only 
- contact to author 
not successful 
Hautala AJ et 
al. 201733 
Finland 
RCT a. EFEX-CARE 
(Effectiveness of 
Exercise Cardiac 
Rehabilitation) 
database of the 
Finnish Health care 
setting 
b. N=204 
c. ACS 
d. 02/2011 ?05/2014 
e. Exclusion criteria: 
NYHA A?/// ?ƐĐŚĞĚƵůĞĚ
or emergency CABG, 
UA, severe 
peripheral 
atherosclerosis, 
diabetic retinopathy 
or neuropathy, 
inability to perform 
regular home-based 
exercises (i.e. severe 
musculoskeletal 
problems) 
a. n=109 (drop-out, 
n=31) 
b. SMC-CR 
c. within 1 wk after 
hospital discharge 
d. 1 y 
e. n=4-5 (1 in hospital 
session per wk and 
home-based sessions 
for 6 mo; thereafter 
home based only) + 
information, 
motivation, 
education, social and 
vocational support 
f. outpatient 
a. n=95 (drop-out, 
n=25) 
b. UC 
a. 1 y 
b. (10)  
c. Health care 
costs, quality-
adjusted life 
years, cost-
effectiveness 
Event rate (%CR+/no 
CR) 
Endpoint 10 after 1y: 
(combination of death, 
recurrent acute 
coronary event, or 
hospitalization for HF)  
4.6/16.8, p=0.004 
- Center-based CR 
under supervision of 
cardiologists and 
physiotherapists, all 
components of SMC-
CR were available to 
most of the patients,  
no information 
about psychological 
support  
(information 
provided by the 
author) 
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f. 60±11 (CR+), 62±9 
(no CR) 
g. 73 (CR+), 71 (no CR) 
Doimo S et al. 
201832 
Italy 
rCCS a. Patients discharged 
from two tertiary 
hospitals 
b. N=1,280  
c. mixed population; 
STEMI (n=378), 
NSTEMI (n=265), 
CABG with or 
without valve 
surgery (n=353) or 
planned PCI (n=284) 
d. 01/01/2009 ?
31/12/2010 
e. Non-residents in the 
region or with severe 
non-cardiac 
comorbidities (i.e. 
end-stage tumors), 
dementia, or 
immobilized 
patients, were 
excluded from the 
CR group. 13% of 
eligible patients did 
not attend CR 
f. 68±11 (CR+), 66±12 
(no CR) 
g. 68 (CR+), 75 (no CR) 
a. n=839; STEMI 
(n=251), NSTEMI 
(n=162), CABG 
(n=243), PCI (n=183) 
b. SMC-CR 
c. 89 d (average)  
d. 5 mo (average) 
e. 1st part (10 
sessions of 45min of 
cyclette training 2 
times/wk for 5 wks); 
2nd part (18 sessions 
of 45min of gym 
training 3 times/wk 
for 6wks) supervised 
by trained nurse and 
physiotherapist.  
Other components: 
Lifestyle counseling 
at every visit + 
nutritional advice 
once/mo + 
psychological support 
a. outpatient  
a. n=441; STEMI 
(n=127), 
NSTEMI 
(n=103), CABG 
(n=110), PCI 
(n=101) 
b. CR non-
attenders 
receiving all 
other 
components of 
CR 
a. Mdn 82 mo  
(IQR 60  ? 89 mo) 
b. PEP: (9) 
SEP: (1), (2), (6) 
c.  effect of CR in 
various 
subgroups 
Event rate (%CR+/no 
CR) 
Endpoint 1: 17/18 
(p=0.861) 
Endpoint 2: 6/6  
(p=0.623) 
Endpoint 6: 15/27 
(p<0.001)) 
Endpoint 9: 18/30 
(p<0.001)) 
HR (95% CI) 
Endpoint 9: 0.578 
(0.432 ?0.773); p<0.001 
Event rate, propensity 
matched analysis 
(%CR+/ no CR) 
Endpoint 1: 10/19 
(p=0.002) 
Endpoint 2: 2/7 
(p=0.008) 
Endpoint 6: 25/11 
(p<0.001)) 
Endpoint 9: 29/13 
(p<0.001)) 
- Group allocation by 
different hospitals 
- Multivariable 
regression model 
and propensity 
score matching 
analysis (covariates: 
age, sex, 
hypertension, LVEF, 
DM, smoking, CKD, 
dyslipidaemia, 
previous PCI, 
previous ACS, BB, 
ACEi/ARB, 
statins/ezetimibe) 
- statistical analysis 
does not address 
cardiovascular 
mortality 
adequately 
- 5-year composite 
endpoint as primary 
outcome 
(hospitalization for 
cardiovascular 
causes and 
cardiovascular 
mortality) 
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Descriptive values of metric variables are given in mean or mean plus standard deviation (SD), if applicable. Other calculations are noted in the table. Mdn, median; N, 603 
number of total population, n, number of subpopulation; d, days; wk, week(s); mo, month(s); y, year(s)  604 
ACEi, angiotensin converting enzyme inhibitors; (A)MI, (acute) myocardial infarction; AP, angina pectoris; ARB, angiotensin receptor blockers; CABG, coronary artery bypass 605 
grafting; BB, beta-blockers, ACEi/ARB CAD, coronary artery disease; CKD, chronic kidney disease; CR, cardiac rehabilitation; DM, diabetes mellitus; HF, heart failure; IHD, 606 
ischemic heart disease; IQR, interquartile range; LAD, left anterior descending coronary artery; LMCA, left main coronary artery; LVEF, left ventricular ejection fraction; pCCS, 607 
prospective controlled cohort trial; PCI, percutaneous coronary intervention; PEP, primary endpoint; QoL, quality of life; rCCS, retrospective controlled cohort trial; RCT, 608 
randomized controlled trial; SEP, secondary endpoint; SMC-CR, structured and multi-component CR; (N) STEMI, (non) ST-elevation myocardial infarction; UC, usual care 609 
including ambulatory supervision by family doctor and/or cardiologist, and may also include advise to exercise at home 610 
Sunamura M 
et al. 201850 
The 
Netherlands 
rCCS a. Patients from 
Erasmus Medical 
Centre (no CR), 
Rotterdam were 
propensity score 
matched with 
patients from Capri 
Cardiac 
Rehabilitation Cater, 
Rotterdam (CR+) 
b. N=3,958 
c. ACS followed by 
primary PCI  
d. 2003 - 2011  
e. Excluded: patients 
with cardiogenic 
shock (2.3%) and 
with early (within 60 
d post-PCI) death 
(5.2%) 
f. 59.0±9.9 (CR+),  
58.8±11.83 (no CR) 
g. 77 (CR+), 78 (no CR) 
a. n=1,159 
b. SMC-CR 
c. Mdn 4-6 wk 
d. 12 wk 
e. n=2 (1.5h group 
exercise session). 
Other components: 
verbal and written 
instructions on how 
to deal with exercise, 
diet, smoking 
cessation, and stress 
management. 
Individual 
consultations with 
psychiatrist, 
psychologist, and 
social workers was 
available if 
necessary. Complete 
CR if attended at 
least 75% of the 
physical program 
f. outpatient 
a. n=1,159 
b. no CR 
participants 
a. Mdn 10 y 
4-12 y (range) 
b. (1) 
c. Mortality rates 
of CR 
completion vs 
non-completion 
Cumulative rates  
(% CR+/no CR) 
Endpoint 1 at 5 y: 
6.4/10.4 
Endpoint 1 at 10 y: 
14.7/23.5 
HR (95% CI) 
Endpoint 1 at 10y: 
(unadjusted) 0.56 (0.43-
0.73) 
(adjusted) 0.61 (0.46-
0.81); p<0.001 
- Propensity score 
matching analysis 
1:1 (covariates:  
age, sex, STEMI, 
current smoking, 
family history of 
CAD, HTN, 
hypercholesterolem
ia, DM, prior MI, 
prior history of PCI 
or CABG, proximal 
LAD lesion, 
socioeconomic 
status) 
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Table 2. Summary of results 612 
Outcome 
Population  
(number of 
Studies) 
Design  
(number of 
Studies) 
Events/number  
of patients (CR) 
Events/number 
of patients 
(control) HR (95% CI) 
OR (95% CI);  
pooling method 
Heterogeneity:  
I2; tau2; p-value 
Total mortality ACS (11) RCT (1) 82/903 84/910 1.01 (0.85-1.21)  NA 
  pCCS (4) NO/3,519 NO/2,063 0.37 (0.20-0.69)  18%; 0.092; p = 
0.30 
  rCCS (4) NO/12,033 NO/24,266 0.64 (0.53-0.76)  33%;0.011; p = 
0.22 
  rCCS (2) 109/2,901 241/1,846  0.20 (0.08-0.48); MH 60%; 0.288; p = 
0.11 
 CABG (6) RCT (1) 0/18 0/18  1.00 (0.02-53.12); 
NA 
NA 
  pCCS (1) 1/149 5/89  0.11 (0.01-0.99); NA NA 
  rCCS (4) NO/5,109 NO/7,889 0.62 (0.54-0.70)  0%; 0; p = 0.71 
 Mixed (10) pCCS (2) 254/3,407 398/2,939 0.66 (0.55-0.79)  0%; 0; p = 0.72 
  rCCS (5) NO/2,606 NO/3,577 0.52 (0.36-0.77)  84%;0.145; p < 
0.01 
  rCCS (3) 1,700/71,674 3,806/71,160  0.68 (0.34-1.37); NA 94%; 0.339; p < 
0.01 
Cardiovascular 
mortality 
ACS (2) pCCS (1) 18/2,505 32/1,042 0.44 (0.24-0.82)  NA 
  pCCS (1) 0/37 1/37  0.32 (0.01-8.23); NA NA 
 CABG (2) pCCS (1) 0/18 0/18  1.00 (0.02-53.12); 
NA 
NA 
  rCCS (1) NO/527 NO/4,747 0.64 (0.51-0.81)  NA 
 Mixed (3) pCCS (1) 37/507 75/507 0.54 (0.36-0.80)  NA 
  rCCS (1) 34/719 46/719 0.67 (0.44-1.03)  NA 
  rCCS (1) 48/839 28/441  0.90 (0.55-1.45); NA NA 
MACCE ACS (2) pCCS (1) 81/2,376 81/971 0.55 (0.39-0.77)  NA 
  rCCS (1) 212/2,756 281/1,791  0.70 (0.35-1.40); NA NA 
 Mixed (1) rCCS (1) 158/785 206/1,224 0.85 (0.74-0.98)  NA 
Non-fatal ACS (3) RCT (1) 7/162 8/115  0.60 (0.21-1.72); NA NA 
myocardial infarction  pCCS (1) 43/2,362 27/946 0.75 (0.45-1.26)  NA 
  pCCS (1) 0/37 0/37  1.00 (0.02-51.73); 
NA 
NA 
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 CABG (1) pCCS (1) 3/343 13/334  0.22 (0.06-0.77); NA NA 
 Mixed (3) pCCS (1) 15/507 23/507 0.65 (0.34-1.26)  NA 
  rCCS (1) NO/785 NO/1,224 1.01 (0.74-1.37)  NA 
  rCCS (1) 14/795 26/679  0.45 (0.23-0.87); NA NA 
Non-fatal stroke ACS (2) RCT (1) 0/162 1/115  0.23 (0.01-5.81); NA NA 
  pCCS (1) 10/2,364 13/954 0.35 (0.14-0.85)  NA 
 Mixed (1) pCCS (1) 8/507 13/507 0.92 (0.24-3.52)  NA 
Hospital readmission ACS (3) pCCS (2) 794/2,447 351/1,035  0.96 (0.81-1.13); IV 0%; 0; p = 0.32 
for any reason  rCCS (1) NO/878 NO/824 1.00 (0.82-1.22)  NA 
 CABG (1) RCT (1) 3/18 1/18  3.40 (0.32-36.27); 
NA 
NA 
 Mixed (2) pCCS (1) NO/2,900 NO/2,432 0.77 (0.71-0.84)  NA 
  rCCS (1) 253/795 258/679  0.76 (0.61-0.94); NA NA 
Unplanned 
readmission 
ACS (2) RCT (1) 23/162 16/115  1.02 (0.51-2.04); NA NA 
for any cardiovascular   pCCS (1) 17/74 20/54  0.51 (0.23-1.10); NA NA 
event Mixed (2) pCCS (1) 32/2,900 109/2,432 0.68 (0.55-0.84)  NA 
  rCCS (1) 122/839 119/441  0.46 (0.35-0.61); NA NA 
Unplanned coronary ACS (1) pCCS (1) 4/69 7/72  0.57 (0.16-2.05); NA NA 
revascularization CABG (1) pCCS (1) 44/343 49/334  0.86 (0.55-1.33); NA NA 
 Mixed (1) pCCS (1) 44/507 33/507 1.38 (0.88-2.16)  NA 
  rCCS (1) 33/795 37/679  0.75 (0.46-1.22); NA NA 
Cardiovascular 
mortality 
ACS (1) pCCS (1) 0/74 4/54  0.08 (0.00-1.43); NA NA 
and readmission Mixed (1) rCCS (1) 155/839 133/441 0.58 (0.43-0.77)  NA 
Combined endpoints ACS (8) RCT (1) 5/109 16/95 0.26 (0.09-0.73)  NA 
  RCT (1) 24/162 25/115  0.63 (0.34-1.15); NA NA 
  pCCS (1) NO/521 NO/522 0.65 (0.30-1.41)  NA 
  pCCS (4) 47/620 69/567  0.58 (0.33-1.00); MH 21%; 0.080; p = 
0.28 
  rCCS (1) 183/2,756 263/1,791  0.41 (0.34-0.50); NA NA 
 CABG (2) RCT (1) 2/18 7/18  0.20 (0.03-1.13); NA NA 
  pCCS (1) 44/343 68/334  0.58 (0.38-0.87); NA NA 
 Mixed (2) rCCS (1) NO/785 NO/1,224 0.77 (0.65-0.91)  NA 
  rCCS (1) 259/795 263/679  0.73 (0.59-0.91); NA NA 
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ACS, acute coronary syndrome; CABG, coronary artery bypass grafting; NO, sum of events has not been calculated, if one study of a specific subgroup did not report the 613 
number of events; MH, Mantel-Haenszel pooling; NA, not applicable; IV, inverse variance pooling; RCT, randomised controlled trial; rCCS, retrospective controlled cohort 614 
study; pCCS, prospective controlled cohort study; HR, hazard ratio; CI, confidence interval; OR, odds ratio. 615 
  616 
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Table 3a. Quality evaluation of cohort studies included into meta-analysis20,21  617 
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Boulay 200451 R 3 + 1  Y N? Y? Y? N Y?  Y 4,7 N Y N NA  Y N 1,2,7  N NA 
Norris 200452 R 8 (+) 2  N N Y N? N Y?  Y 1 N Y N N  Y Y 1,2,4-7  Y a,c,d 
Kutner 200653 R 7 A? 3  N N NC NC N Y?  Y 1,2 N Y N N  Y Y 1,2,4,6  Y a,d 
Milani 200754 R 6 + 4  N N Y NC N Y  Y 1 N N N N  Y N 1,2,4,7  Y a,d 
Nielsen 200855 R 8 + 5  N N NC NC N Y?  Y 1,4 N Y N N  Y N 1,2  Y a 
Alter 200956 R 8 + 6  N N Y Y N Y?  Y 1 Y Y N N  Y Y 1,2,4,6  Y a,d,e 
Hansen 200957 P 6 + 7  N Y Y NC N N  Y 1,4,8,10 N Y? N N  Y N 1,2-4,8  Y a,d 
Suaya 200958 R 7 (+) 6  N N Y? Y? N NC  Y 1 N Y N N  Y Y 1,2,4-7  Y a,b,d 
Jünger 201059 R 7 (+) 8  N N Y Y N Y  Y 1,3,10 Y Y N N  Y N 1-8  Y a,c,d 
Goel 201160 R 7 (+) 6,15  N N Y Y N Y?  Y 1,2,4,8,10 N Y N N  Y Y 1-8  Y b,c,d 
Kim 201128 P 4 (+) 9  N N NC Y N NC  Y? 1,6,8,10 N NC NC NA  Y N 1,2,4,7  N NA 
Schwaab 201131 R 6 (+) 10  N NC Y Y N NC  Y? 1,4,6,8 N NC N N  Y N 1,2,7  Y a 
Martin 201261 P 7 (+) 11  N N Y Y? N Y?  Y? 1,6,7 Y Y N N  Y NC 1-8  Y a,b 
Beauchamp 201362 R 7 (+) 12  N N Y Y N NC  N? 1 N N N NC  N N 1,2,4  Y a 
Lee 201363 P 8 (+) 13  N N Y Y N NC  Y 2,4,10 N N N? N  N N N  N NA 
Marzolini 201364 P 8 A? 14  N N Y Y N Y  Y? 1,10 Y Y N N  Y Y 1-4  Y a,c 
Pack 201365 R 7 + 15  N N Y Y N Y?  Y 1 N N N N  Y Y 1-7  Y a-d 
Coll-Fernandez 201466 P 8 A? 16  N N Y Y? N NC  Y 1,10 N N N N  Y Y 1-4,8  Y a,d 
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Prince 201467 R 6 A? 17  N N Y Y N Y?  Y 1 N N N N  Y N 1,2  Y a 
Rauch 201468 P 8 + 18  N N Y Y N Y  Y 1-6,8 Y Y N N  Y Y 1-8  Y a,c,d 
Goel 201369 R 7 (+) 15  N N Y Y N Y?  Y 1 N N N N  Y Y 1-3,5  Y a,c,d 
De Vries 201527 R 7 + 19  N N Y Y N Y  Y 1 Y N N N  Y Y 1,2,4,5,7  Y a,c,d 
Meurs 201570 R 5 (+) 20  N N Y Y N Y  Y 1,6 N Y N N  Y Y 1,2,6,7  Y a,d 
Schlitt 201571 R 4 (+) 21  N N Y Y N NC  Y 1 N Y N NC  Y N 1-7  Y a,d 
Lee 201649 P 7 + 22  N N Y NC N Y?  Y 1,4,5,8 Y N N N  Y N N  Y a,b 
Espinosa Caliani 200448 P 6 + 23  N NC NC Y N NC  NC 10 N N N N  N N N  N NA 
Doimo 201832 R 5 + 6, 24  N Y NC NC N Y?  Y 1,7,9,10 N N N N  Y N 1-4,6,7  Y a,d 
Sunamura 201850 R 7 + 7  N NC NC NC N NC  Y 1 N N N N  Y N 1-4,6  Y a-d 
                          
༣ Reporting of CR-characƚĞƌŝƐƚŝĐƐ PA? ?ƐƵĨĨŝĐŝĞŶƚ ? ?A? ? ?ŝŶĨŽƌŵĂƚŝŽŶŽďƚĂŝŶĞĚďǇĂƵƚŚŽƌŽƌŽƚŚĞƌƐŽƵƌĐĞƐ ?A? ?ŝŶĨŽƌŵĂƚŝŽŶůŝŵŝƚĞĚ 618 
* specific actions to compare groups: (1) prospectively evaluated intervention group versus retrospectively evaluated control group; (2) linkage of Canadian APPROACH and 619 
NACPR registry; (3) data extracted from the United States renal data System, USRDS; (4) retrospective identification of groups by questionnaires within a predefined study 620 
cohort; (5) retrospective identification of groups in a population surviving AMI for at least 30 d; (6) retrospective evaluation and formation of matched pairs; (7) groups were 621 
formed by two hospitals following different CR referral policies; (8) retrospective identification of groups by questionnaires and personal contact to relatives of deceased 622 
patients; (9) groups were formed prospectively according to predefined inclusion and exclusion criteria; (10) retrospective definition of the study groups out of an 623 
independent pre-existing study cohort on the basis of medical records;72 (11) propensity score matching; (12) retrospective evaluation of a pre-existing cohort of another 624 
study evaluating CR attendance after automatic referral; (13) predefinition of inclusion and exclusion criteria, but final group formation by patient`s preferences and health 625 
care decision makers; (14) selection of CAD-patients with musculoskeletal disease in addition. (15) retrospective definition of the groups; CR+ group was defined as attending 626 
at least one session within 6 mo after the index event; (16) prospective definition of the groups out of the FRENA registry;73 (17) patients referred to CR but not attending 627 
served as control; (18) groups were pre-specified from the OMEGA-trial cohort;74 (19) 180 days survival after index event required; (20) study population has been extracted 628 
from two pre-existent studies (DepeMI, MIND-IT);75,76 (21) retrospective recruitment of study population from two previous RCT not investigating CR or prognostic CAD 629 
outcomes;71,77 (22) data extracted from ASAN Medical Center-Left MAIN Revascularization registry and ASAN Medical Center cardiac rehabilitation database; (23) control 630 
group was formed of patients who did not accept CR program; (24) matching pairs from the Capri Cardiac Rehabilitation database and Erasmus Medical Centre database 631 
(control) 632 
 ?Outcomes under investigation: the numbers refer to the predefined outcomes as outlined in Table 1. 633 
 ?Confounding domains as specified by CROS: 1, age; 2, sex; 3, smoker; 4, diabetes; 5, history of stroke; 6, history of acute myocardial infarction; 7, reduced left ventricular 634 
ejection fraction; 8, acute/early 635 
percutaneous coronary intervention during acute myocardial infarction. 636 
§ Biometrical methods to manage confounding: (a) multivariable regression analysis; (b) propensity score matching; (c) propensity score-adjusted multivariable regression 637 
analysis; (d) confounders described; (e) retrospective matched pairs. Adjusting only for age and gender has been regarded as insufficient for the limitation of confounding. 638 
APPROACH, Alberta Provincial Project for Outcomes Assessment in Coronary Heart Disease; NACRP, Northern Alberta Cardiac Rehabilitation Program; FRENA, Risk Factors 639 
and Arterial Disease registry (Factores de Riesgo y ENfermedad Arterial); OMEGA, Randomized, Placebo-Controlled Trial to Test the Effect of Highly Purified Omega-3 Fatty 640 
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Acids on Top of Modern Guideline-Adjusted Therapy after Myocardial Infarction; DepreMI, Depression after Myocardial Infarction study; MIND-IT, Myocardial Infarction 641 
and Depression Intervention Trial. 642 
R, retrospective cohort control study; P, prospective cohort control study; Y, yes; Y?, probably yes; N, no; N?, probably no; NC, not clear, not reported; NA, not applicable;  643 
green Æ adjudication is in favor to reliability of results and reporting; 644 
yellow Æ item potentially increases risk of limited reliability of results and reporting; 645 
red Æ item increases risk of reliability of results and reporting. 646 
  647 
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 648 
Table 3b. Quality evaluation of randomised controlled trials included into meta-analysis (according to the Cochrane risk of bias table)  649 
Risk West 201214 Aronov 201730 Hautala 201733 
Under-powering High risk High risk  Unclear risk 
Selection bias Unclear risk Unclear risk Low risk 
Random sequence selection bias Unclear risk High risk Low risk 
Allocation concealment Low risk High risk Unclear risk 
Confounding variables Unclear risk High risk Low risk 
Performance bias Low risk Unclear risk Low risk 
Detection bias Low risk Unclear risk Low risk 
Attrition bias (incomplete outcome data) Low risk Low risk Low risk 
Groups balanced at baseline Low risk Unclear risk Low risk 
Groups not receiving the same baseline 
treatment 
Unclear risk Low risk Low risk 
Intention to treat analysis Low risk Low risk Low risk 
Reporting bias Low risk Low risk Low risk 
Comments Low recruitment (22.5% CR arm; 22.7% 
control arm), study participation 
influenced by patient`s preferences, 
random sequence generation is not 
reported, per protocol centrally organized 
randomization and blinded with respect 
to baseline characteristics, confirmation 
of exposure sufficient, CR status has been 
blinded before outcome assessment, 
follow-up reporting was completed in 
95% of surviving patients, baseline 
treatment with respect to medication and 
medical supervision has to be assumed; 
control group may also have received life 
style support to a variable extend 
No primary endpoint defined; no pre-
estimation of sample sizes and effect sizes 
were described with respect to any 
endpoint measured), exclusively low risk 
patients, no randomization method 
described, potential confounding 
variables were not assessed, no allocation 
concealment, interactions between the 
study groups confounding performance 
cannot be excluded, Baseline values were 
presented in a descriptive way without 
statistical evaluation. At least in n=3 
relevant clinical characteristics a balance 
between groups was not achieved   
Primary endpoint: Cost / quality-adjusted 
life year of a cardiac patient (QALY)  
Secondary endpoint: Major Adverse 
Cardiac Event (MACE) 
Statistical power of the study has not 
been reported with respect to either of 
the presented endpoints 
green Æ adjudication is in favour to reliability of results and reporting; yellow Æ item potentially increases risk of limited reliability of results and reporting; red Æ item 650 
increases risk of reliability of results and reporting. 651 
 652 
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Figure legends 653 
Figure 1. Study selection flow chart 654 
a Other reasons PS level: reviews, letters, study protocol, only abstract available, b Other reasons FTE level: referral 655 
only, referral only, no information about CR enrollment and adherence available. ICTRP: International Clinical Trials 656 
Registry Platform; PS: primary selection of extracted studies; FTE: full-text evaluation; SSE: structured study 657 
evaluation and quality analysis according to the checklist of methodological issues on non-randomized studies.20  658 
Figure 2. Analysis of total mortality 659 
&ŽƌĞƐƚ ƉůŽƚƐ ƉƌĞƐĞŶƚŝŶŐ ƚŚĞ ĞǀĂůƵĂƚŝŽŶ ŽĨ ƚŚĞ ĞŶĚƉŽŝŶƚ  “ƚŽƚĂů ŵŽƌƚĂůŝƚǇ ? ? ,Z ? ,ĂǌĂƌĚ ƌĂƚŝŽ ? KZ ? KĚĚƐ ƌĂƚŝŽ ? D, ?660 
Mantel-Haenszel pooling method; CR, cardiac rehabilitation; no CR, no cardiac rehabilitation (control); CI, confidence 661 
interval; Events, number of events in the evaluated group; Total, number of patients in the evaluated group; Start 662 
(w), start of cardiac rehabilitation after hospital discharge in weeks; Follow-up, follow-up in years. 663 
